Efficacy of DCTAA combined with CIK in treatment of patients with moderate and advanced stage lung cancer

Objective To observe the efficacy in 48 patients with moderate and advanced lung cancer treated by immuno therapy of the dendritic cells loading of tumor autologous antigen(DC~(TAA)) combined with the cells induced factor of the killer cells(CIK) from the matched umbilical cord blood cells.Methods The peripheral blood mononuclear cells(PBMC) were separated from the matched umbilical cord blood cells,induced to CIK and DC with some cytokines in vitro,such as CD3McAb,IL-2,IFN-γ,IL - 1α,etc.After 12 to 15 days,we obtained the amplified CIK cells and infused the CIK cells back to the patients'body six times under strict quality control, about 5 -8×10~9 CIK cells in each time.On the fifth day of the cultivation,we loaded DC with tumor autologous antigen,obtained DC~(TAA) cells on the eighth day,and then gave a hypodermic injection to lymph nodes.The patient's general condition after the immunotherapy was observed,such as the size of the tumor,clinical symptom score,the quality of life and immune indexes,Kamofsky score, weight,toxic and side effects,and the patient's survival was also studied.Results Of the 48 cases undergoing DC~(TAA)-CIK treatment, complete remission(CR) and partial remission(PR) were effected in 37 cases.The overall remission rate was 77.1%.The improvement rate of clinical symptom scores ranged from 78.9%to 84.7%,and the increase rate of Kamofsky score was 89.6%.One - year survival reached 80.6%.Toxic and side effects were trivial with significant difference(P0.01).The proportions of CD3,CD4 and NK cells in peripheral blood cells increased significantly(P0.01) after DC~(TAA)- CIK cells treatment.Conclusions The DC~(TAA) - CIK immuno therapy is effective for advanced lung cancer by not only improving the immune function but also ameliorating clinical symptoms.